Share Prices & Company Research

Stockbroking

Polarean Imaging

Current Price 69.00p Bid 68.00p Ask 70.00p Change -2.27%
Last Updated: 25/11/2020 13:11. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Polarean is a clinical-stage company with a core technology that is a drug-device combination product that enables the visualisation of hyperpolarised 129Xe ("HPX") using MRI technology to help diagnose lung disease earlier, identify the type of intervention likely to benefit a patient, and to monitor the efficacy of treatment. It is currently being used at a number of research sites on a pre-FDA clearance basis to facilitate the research and evaluation of lung function, to assist in making improved disease progression assessment and to clearly visualise the effectiveness of several therapeutics which are under development.

Financial Highlights Year Ended 31/12/2019

Revenue
£2.30m
Operating Profit/Loss
£-6.01m
Dividend yield (%)
n/a
Total dividend for year
$n/a
Dividend cover
n/a
P/E Ratio
n/a

Key Personnel

Mr Jonathan Allis
Chairman
Mr Richard Hullihen
Chief Executive Officer
Mr Kenneth West
Chief Operating Officer
Mr Bastiaan Driehuys
Chief Technology Officer
Mr Cyrille Petit
Non-Executive Director
Mr Juergen Laucht
Non-Executive Director

Stock Details

EPIC
POLX
ISIN
GB00BF3DT583
Shares in Issue
161.83m
Market cap
£111.71m
Sector

Price Summary

Mid Price
69.00p
Bid Price
68.00p
Ask Price
70.00p
Volume
35,690
Change Today
-1.60p
% Change Today
-2.27%
Open
70.00p
Previous Close
70.60p
Intraday High
70.38p
Intraday Low
69.00p
52 Week High
79.50p
52 Week Low
17.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Continuing Operations
Revenue
2.30
2.44
Operating Profit/Loss
-6.01
-5.27
Net Interest
-0.09
-0.19
Pre-Tax Profit
-6.10
-5.45
Profit After Tax from continuing operations
-6.10
-5.45
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
-6.10
-5.45
Attributable to:
Equity Holders of Parent Company
-6.10
-5.45
Minority Interests
n/a
n/a
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
-5.70c
-7.80c
Diluted
-5.70c
-7.80c
Adjusted
-5.70c
-7.80c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
0.45
0.02
Intangible Assets
3.43
4.04
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
0.01
0.01
Current Assets
Inventories
0.55
0.65
Trade & Other Receivables
0.64
4.23
Cash at Bank & In Hand
1.96
0.88
Current Asset Investments
n/a
n/a
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
7.04
9.83

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Current Liabilities
Borrowings
0.07
0.01
Other Current Liabilities
1.82
1.65
Total Current Liabilities
1.89
1.66
Non-Current Liabilities
Borrowings
0.05
n/a
Provisions
0.32
0.32
Other Non-Current Liabilities
0.19
0.07
Total Non-Current Liabilities
0.56
0.39
Other Liabilities
n/a
n/a
Total Liabilities
2.45
2.04

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Net Assets
4.59
7.79

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Share Capital
0.06
0.05
Share Premium Account
13.66
11.06
Other Reserves
9.18
8.89
Retained Earnings
-18.31
-12.21
Shareholders Funds
4.59
7.79
Minority Interests/Other Equity
n/a
n/a
Total Equity
4.59
7.79

Dividend History

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.